Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial

Cancer Science

Volumn 104, Issue 6, 2013, Pages 718-724

  Giessen, Clemens ^a   Laubender, Ruediger P ^b,d   Fischer von Weikersthal, Ludwig ^c   Schalhorn, Andreas ^a   Modest, Dominik P ^a   Stintzing, Sebastian ^a   Haas, Michael ^a   Mansmann, Ulrich R ^b   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Onkologisches Zentrum   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; EARLY TUMOR SHRINKAGE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878178425     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12148     Document Type: Article

References (20)

1. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
2. Piessevaux H, Buyse M, De Roock W et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 2009; 20: 1375-82.
3. Piessevaux H, Schlichting M, Heeger S, Van Cutsem EST. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study. Abstracts of the 35th European Society for Medical Oncology Conference. October 8-12, 2010. Milan, Italy. Ann Oncol. 2010; 21(Suppl 8): viii 189-viii 224.
4. Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and clinical outcome in metastatic colorectal cancer: Analysis of predictive utility in the CRYSTAL and OPUS studies. Oral presentation at the 10th Annual Meeting of the Japanese Society of Medical Oncology (JSMO), Osaka July 28th. 2012.
5. Glimelius B, Sorbye H, Balteskard L et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 909-14.
6. Suzuki C, Blomqvist L, Sundin A et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2012; 23: 948-54.
7. Fischer von Weikersthal L, Schalhorn A, Stauch M et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47: 206-14.
8. Hunter RD. WHO Handbook for Reporting Results of Cancer Treatment. Int J Radiat Biol 1980; 38: 481.
9. Grothey A, Hedrick EE, Mass RD et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26: 183-9.
10. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
11. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
12. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 373-8.
13. Methy N, Bedenne L, Bonnetain F. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists BMC Cancer 2010; 10: 277.
14. Piessevaux H, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial. ASCO Meeting Abstracts 2011; 29(Suppl 4): 398.
15. Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. ASCO Meeting Abstracts 2011; 29(Suppl 15): 3572.
16. Modest DP, Laubender RP, Stintzing S et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol 2012. Epub ahead of print.
17. Mansmann UR, Laubender RP, Giessen CA, Sartorius U, Heinemann V. Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2012; 30(Suppl 4): 580.
18. Fleming TR. Objective response rate as a surrogate end point: a commentary. J Clin Oncol 2005; 23: 4845-6.
19. Claret L, Girard P, Hoff PM et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009; 27: 4103-8.
20. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-19.